CLYM
Climb Bio (CLYM)
$18
About Climb Bio (CLYM)
Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.
Details
Daily high
$12.48
Daily low
$11.51
Price at open
$11.52
52 Week High
$12.48
52 Week Low
$1.17
Market cap
655.7M
Dividend yield
0.00%
Volume
1.4M
Avg. volume
1.3M
P/E ratio
-14.70
Climb Bio News
Details
Daily high
$12.48
Daily low
$11.51
Price at open
$11.52
52 Week High
$12.48
52 Week Low
$1.17
Market cap
655.7M
Dividend yield
0.00%
Volume
1.4M
Avg. volume
1.3M
P/E ratio
-14.70